semaglutide coronary artery disease Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes Frontiers | Anti-inflammatory effects of

2 22% reduction in certain kidney problems for people without type 2 diabetes

I started my weight-loss journey at 288 pounds before my gastric sleeve surgery, and even after surgery, I hit a prolonged stall

And the obesity counterpart from the tirzepatide family, Zepbound, sits at around 5%, even above Wegovy, in keeping with its still greater weight loss of up to minus 22.5%

Content on this page is for educational purposes only and does not constitute medical advice

oral semaglutide, and all included studies were high-quality cardiovascular outcome trials

Furthermore, ongoing studies are exploring its potential cardiovascular and kidney benefits